Jose Mejia Oneto

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “695 Combination of click chemistry-based SQ3370 with immunotherapies enhances antitumor effect in murine tumors with minimized systemic toxicity”.

695 Combination of click chemistry-based SQ3370 with immunotherapies enhances antitumor effect in murine tumors with minimized systemic toxicity

Regular and Young Investigator Award Abstracts(2021)10.1136/jitc-2021-sitc2021.695

N/A

0DataRank · unranked

0 citations

Sangeetha Srinivasan, Michael Zakharian, Nathan K. Yee, Jesse M. McFarland, Jose Mejia Oneto +1 more

953 Treatment with SQ3370, a doxorubicin-based therapeutic, corresponds with immunomodulation of the tumor microenvironment

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0953

N/A

0DataRank · unranked

0 citations

Sangeetha Srinivasan, Jesse M. McFarland, Leslie Priddy, Matthew Tso, Jose Mejia Oneto +1 more

A first-in-human, Phase 1/2a, open-label study of SQ3370, a first-in-class doxorubicin-based click chemistry therapeutic, in patients with advanced solid tumors

medRxiv(2025)10.1101/2025.06.02.25328445

N/A

0DataRank · unranked

2 citations

Esteban Abella, Stefan Wieland, Thu‐Ha Nguyen, Sangeetha Srinivasan, M. Alečković +10 more